Clinical relevance of Fas expression in oesophageal squamous cell carcinoma

被引:15
作者
Chan, KW
Lee, PY
Lam, AKY
Law, S
Wong, J
Srivastava, G
机构
[1] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Griffith Univ, Griffith Med Sch, Dept Pathol, Gold Coast, Qld 9726, Australia
关键词
D O I
10.1136/jcp.2005.027508
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To determine the extent of Fas expression in oesophageal squamous cell carcinomas (ESCCs) from Chinese patients and to correlate Fas expression with clinicopathological prognostic parameters. Methods: Clinicopathological data were collected from 58 patients with ESCC who underwent oesophagectomy and had no prior radiotherapy or chemotherapy. Immunostaining was performed on the primary tumours. Expression of Fas was correlated with patients' demographics, tumour characteristics and stage, R category of surgery, and patients' survival. Results: The actuarial survival rates of all patients at two and five years after surgery were 48% and 14%, respectively. Fas expression was detected in 89.7% of ESCCs. Higher Fas expression recorded on a four point scale correlated with better tumour differentiation (p < 0.01), but not with other patient or tumour variables. Importantly, higher Fas expression was associated with better survival (p = 0.0317). Conclusions: These findings suggest that Fas activated apoptosis is important in the pathogenesis of ESCC. This molecular pathway may be a potential therapeutic target for ESCC.
引用
收藏
页码:101 / 104
页数:4
相关论文
共 22 条
[1]  
*AM JOINT COMM CAN, 2002, AJCC CANC STAG HDB, P101
[2]  
*AM JOINT COMM CAN, 2002, AJCC CANC STAG HDB, P15
[3]   Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover [J].
Bennett, MW ;
O'Connell, J ;
O'Sullivan, GC ;
Roche, D ;
Brady, C ;
Collins, JK ;
Shanahan, F .
DISEASES OF THE ESOPHAGUS, 1999, 12 (02) :90-98
[4]  
Bennett MW, 1998, J IMMUNOL, V160, P5669
[5]  
Gratas C, 1998, CANCER RES, V58, P2057
[6]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[7]  
Gronbaek K, 1998, BLOOD, V92, P3018
[8]  
Hamilton S.R., 2000, WHO CLASSIFICATION T
[9]   FAS AND PERFORIN PATHWAYS AS MAJOR MECHANISMS OF T-CELL-MEDIATED CYTOTOXICITY [J].
KAGI, D ;
VIGNAUX, F ;
LEDERMANN, B ;
BURKI, K ;
DEPRAETERE, V ;
NAGATA, S ;
HENGARTNER, H ;
GOLSTEIN, P .
SCIENCE, 1994, 265 (5171) :528-530
[10]   Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo [J].
Kagi, D ;
Ledermann, B ;
Burki, K ;
Zinkernagel, RM ;
Hengartner, H .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :207-232